RBD correlation with lower levels of CSF alpha-synuclein, as seen here in cases of prodromal and established, PD may provide an important window for treatment with future disease-modifying therapies targeted at halting or preventing alpha-synuclein aggregation. Here, SNCA is linked to Parkinson disease.